Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 17/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30324530 | 1.00 | RIPK1 (0.46) | RIPK1NPC1RAB9ASMN1; SMN2UCHL1 | |
| SCHEMBL22638846 | 0.86 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL30324586 | 0.83 | RIPK1 (0.43) | RIPK1 | |
| SCHEMBL24111135 | 0.83 | RIPK1 (0.43) | RIPK1 | |
| SCHEMBL26049952 | 0.80 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL26049955 | 0.80 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL24154824 | 0.78 | UCHL1 (0.40) | NPC1RAB9ASMN1; SMN2UCHL1USP30 | |
| SCHEMBL22638819 | 0.78 | RIPK1 (0.70) | RIPK1 | |
| SCHEMBL3357225 | 0.77 | UCHL1 (0.52) | RIPK1UCHL1USP30 | |
| SCHEMBL6962727 | 0.77 | UCHL1 (0.52) | RIPK1UCHL1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| EP-4164654-A1 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2021252307-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252307-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885NPC1 760/4885RAB9A 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.